New diabetes management revolution

A new phase of insulin delivery methods promises to transform the way in which UK diabetics manage their condition. Several new methods of insulin delivery are at various stages of advanced development and despite concerns over cost, efficacy and safety, could radically alter diabetes lifestyle in this country.
The eager diabetes community is hungry for improved disease management . Diabetes companies, always aware of the potential scale of their market and the substantial amounts of money to be made, are in something of a race for the finish line. According to Frost &Sulliva, the inhaled insulin market is set to earn revenues in excess of $611.7 million by 2012.
One analyst from the company said: “Compliance is currently a major drawback in current diabetes delivery devices, with several patients suffering from Type 2 diabetes irregularly following or, in some cases, even discontinuing their insulin therapy due to pain or fear of injections. Through more convenient drug delivery methods, pharmaceutical companies, regulatory bodies and other government institutions can introduce better diabetes care and reduce costs related to diabetic complications caused by poor compliance.”
Oral, nanotech, gene therapy and transdermal methods of insulin delivery are under research and in varying stages of completion. Exubera has waded into the market, and further products are expected shortly.